Scrotal Ultrasonography
Customize your policy alerts
Sign up for Aetna Policy 0532 alerts
Get alerted when Policy 0532 changes without checking for updates manually.
Monitor payer policy activity
This policy governs when scrotal ultrasound (including color Doppler) is considered medically necessary or experimental for Aetna members, addressing indications such as masses, torsion, hydrocele, infertility, trauma, varicocele, and cryptorchidism.
No material clinical or coverage changes in this revision.
Medical Necessity and Investigational Indications
Medical Necessity Indications
Covered when any of the following indications are present:
List taken verbatim from policy medical necessity section.
Experimental / Investigational
Considered experimental/investigational for the following:
Policy states TM surveillance without other risk factors is experimental/investigational; ESUR guidance and pooled analyses do not support routine follow-up for isolated TML.
Testicular torsion - whirlpool sign evidence
Clinical utility and evidence summary for the whirlpool sign in suspected testicular torsion:
Meta-analysis results summarized from McDowall et al.; removal of neonates increases sensitivity while specificity remains ~0.99.
Benign testicular lesions evaluation
Guiding statements for imaging assessment of suspected benign scrotal/testicular lesions:
Based on case series and expert summaries describing leiomyomas and other benign testicular lesions; role of contrast-enhanced US is investigational and further research is needed.
Aetna does not support routine surveillance scrotal ultrasound for isolated testicular microlithiasis when no additional risk factors are present. Surveillance imaging in this scenario is considered experimental and investigational and is not supported by the policy unless other risk factors (for example, history of cryptorchidism, testicular atrophy <12 ml, or prior testicular cancer) are documented.
The diagnostic performance of the whirlpool sign for testicular torsion is reduced when neonatal patients are included in analyses. Meta-analysis data show improved sensitivity after excluding neonates (pooled sensitivity increased to 0.92) compared with the overall pooled sensitivity (0.73), indicating a more limited role for this sign in neonates.
Routine surveillance imaging for testicular microlithiasis in the absence of additional risk factors is considered experimental/investigational. Requests for scrotal ultrasonography solely for TM surveillance without documented qualifying risk factors may be reviewed as not medically necessary.
Billing Codes and Diagnostic Thresholds
| 76870 | Ultrasound, scrotum and contents |
| C63.2 | Malignant neoplasm of scrotum |
| D29.4 | Benign neoplasm of scrotum |
| D40.10 | Neoplasm of uncertain behavior of testis |
| D40.11 | Neoplasm of uncertain behavior of testis |
| D40.12 | Neoplasm of uncertain behavior of testis |
| I86.1 | Scrotal varices |
| N43.0 | Hydrocele |
| N43.1 | Spermatocele |
| N43.2 | Hydrocele and spermatocele |
| N43.42 | Hydrocele and spermatocele |
Provider Requirements, Prior Authorization, and Documentation
Prior Authorization / Code Coverage
Prior authorization is not specified for scrotal ultrasonography in the source document. CPT 76870 (Ultrasound, scrotum and contents) is covered when the applicable medical necessity/selection criteria in this policy are met.
- Covered CPT when medically necessary: 76870
No Prior Authorization Specified
No additional prior authorization or step-therapy requirements are specified in the provided policy chunks. Providers should follow usual payer enrollment and claims submission processes.
- None specified in these document chunks
Required Indication Documentation
Documentation submitted with the authorization request or claim must support one of the medically necessary indications listed in this policy (e.g., detection/characterization of scrotal mass or tumor; evaluation of suspected testicular torsion; evaluation of hydrocele, varicocele, scrotal pain/swelling, scrotal trauma; infertility evaluation; evaluation of undescended testes when indicated). Ensure clinical notes describe presenting symptoms, physical exam findings (palpable vs non-palpable testis), relevant risk factors (e.g., history of cryptorchidism, testicular atrophy, prior testicular cancer), and how ultrasound results will affect management.
- Required documentation: clinical indication, relevant history, physical exam findings, rationale for imaging and how results will change management
Imaging Stewardship for Cryptorchidism
Imaging stewardship for cryptorchidism: ultrasound should not be routinely ordered to locate non-palpable testes because imaging lacks sufficient sensitivity and specificity to replace exploratory surgery. Reserve ultrasonography for specific situations where imaging may alter management, such as: to look for gonads or a uterus in a phenotypically male infant with bilateral non-palpable testes (evaluation for disorder of sexual development), or in obese boys where intra-canalicular testes are difficult to palpate and imaging may change the surgical approach.
- Do not routinely image non-palpable testes; consider ultrasound only for specific indications noted above
Clinical Background and Scope
Scrotal ultrasound, including color Doppler, is highly sensitive for detecting intratesticular abnormalities and is the imaging modality of choice for differentiating intratesticular from paratesticular lesions and for assessing scrotal blood flow (for example, in suspected torsion). It is the first-line study for evaluation of scrotal masses, acute scrotal symptoms, hydrocele, trauma, infertility assessment, and varicocele (intra-scrotal veins > 2 mm are consistent with varicocele).
Definitions and Diagnostic Signs
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.